Compare BridgeBio Pharma Inc (BBIO) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Kinross Gold Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Kinross Gold Corporation trades at $27.84 (market cap $32.29B). The key difference: Kinross Gold Corporation is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.59% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KGC | |
|---|---|---|
Market Cap | $16.36B | $32.29B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $38.06 |
52-Week Low | $47.29 | $18.70 |
Enterprise Value | $18.14B | $30.37B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KGC trades at $27.40, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $0.71 per share, beating estimates, and maintains robust fundamentals with a P/E of 10.36 and net income margin of 37.52%. Recent news includes an S&P credit upgrade to 'BBB' and progress on the Lobo-Marte project, signaling operational strength.
The outlook is positive, driven by earnings beats, rising free cash flow, and a consensus price target of $37.20 offering ~36% upside. Risks include cost pressures, gold price volatility, and execution of growth projects. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor Q3 2026 results for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
